Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Sarcoma 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Liposarcoma 5Sarcoma 4Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Medulloblastoma 1Liposarcoma, Myxoid 1Lipoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Glioma 1Gastrointestinal Stromal Tumors 1Fibrosarcoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Disorders of Sex Development 1Dermatofibrosarcoma 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Cyclophosphamide 39Peripheral Blood Stem Cell Transplantation 32fludarabine phosphate 30Busulfan 26Filgrastim 24Cyclosporine 24Mycophenolic Acid 22Antilymphocyte Serum 22Radiotherapy 20Melphalan 16Whole-Body Irradiation 15Tacrolimus 14Methylprednisolone 14Methotrexate 13Cord Blood Stem Cell Transplantation 12Etoposide 10sargramostim 5Thiotepa 5Temozolomide 5Sirolimus 5Rituximab 5Bevacizumab 5aldesleukin 4Therapeutics 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4Carmustine 4pembrolizumab 3Vincristine 3Topotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × ribociclib × Sarcoma × Clear all
NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Novartis

Phase 1 Terminated
12 enrolled
CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡